Cymabay Therapeutics (CBAY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
32.48 +0.01 (+0.03%) 03/21/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 32.48 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -105,370 | -106,001 | -89,998 | -50,986 | -102,808 |
| Depreciation Amortization | -7,183 | -249 | 1,306 | 528 | -1,665 |
| Accounts payable and accrued liabilities | 2,732 | -1,444 | 2,309 | -2,272 | N/A |
| Other Working Capital | 5,632 | -2,339 | 6,351 | -1,591 | -3,906 |
| Other Operating Activity | 31,658 | 25,953 | 10,601 | 9,596 | 10,468 |
| Operating Cash Flow | $-72,531 | $-84,080 | $-69,431 | $-44,725 | $-97,911 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -86,124 | -45,837 | 48,676 | 47,978 | -34,032 |
| PPE Investments | -445 | -148 | -87 | -21 | -315 |
| Investing Cash Flow | $-86,569 | $-45,985 | $48,589 | $47,957 | $-34,347 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 25,000 | 47,737 | N/A | N/A |
| Common Stock Issued | 345,772 | -450 | 70,718 | 92 | 108,132 |
| Financing Cash Flow | $345,772 | $24,550 | $118,455 | $92 | $108,132 |
| Beginning Cash Position | 20,291 | 125,806 | 28,193 | 24,869 | 48,995 |
| End Cash Position | 206,963 | 20,291 | 125,806 | 28,193 | 24,869 |
| Net Cash Flow | $186,672 | $-105,515 | $97,613 | $3,324 | $-24,126 |
| Free Cash Flow | |||||
| Operating Cash Flow | -72,531 | -84,080 | -69,431 | -44,725 | -97,911 |
| Capital Expenditure | -445 | -148 | -87 | -21 | -315 |
| Free Cash Flow | -72,976 | -84,228 | -69,518 | -44,746 | -98,226 |